MilliporeSigma
  • Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.

Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.

Cancer chemotherapy and pharmacology (2003-05-17)
Miranda Verschraagen, Epie Boven, Ivon Zegers, Frederick H Hausheer, Wim J F Van der Vijgh
ABSTRACT

BNP7787 (2',2'-dithio-bis-ethane sulfonate sodium) is a novel protector against cisplatin-induced toxicities. The pharmacokinetics of BNP7787 and its metabolite mesna were investigated in plasma and ascites of a cancer patient. We also evaluated potential pharmacokinetic interactions between BNP7787 and cisplatin. BNP7787 and mesna were measured as mesna in deproteinized plasma and ascites using high-performance liquid chromatography with an electrochemical detector provided with a wall-jet gold electrode. After the i.v. administration of 41 g/m(2) BNP7787, BNP7787 and mesna had a half-life of 1.5 and 3.4 h, respectively. The AUC( infinity ) of mesna was approximately 8% of the AUC( infinity ) of BNP7787. Coadministration of cisplatin did not appear to influence the plasma concentration-time curves of BNP7787 and mesna. In ascites, approximately 0.02% of the BNP7787 dose was present as mesna, whereas approximately 4% of the dose was present as BNP7787 at the time of the maximum concentration. It can be concluded that the presence of ascites did not have a major impact on the pharmacokinetics of BNP7787 and coadministration of cisplatin did not influence the pharmacokinetics of BNP7787 and mesna.

MATERIALS
Product Number
Brand
Product Description

Mesna impurity D, European Pharmacopoeia (EP) Reference Standard